US health officials have reportedly discussed the possibility of restricting certain widely prescribed antidepressant drugs, even as the Health Department has denied any formal plan to ban them.
According to people familiar with internal discussions, attention has focused on a class of medications known as selective serotonin reuptake inhibitors (SSRIs), which include commonly used antidepressants such as sertraline (Zoloft), fluoxetine (Prozac) and escitalopram (Lexapro). These medicines have been in use across the United States for decades.
However, officials have not confirmed which specific drugs were being considered, nor the extent of any potential review.
The Health and Human Services Department has denied that any official ban is under consideration, stating that such claims are inaccurate.
At the same time, the department has announced new initiatives aimed at reducing reliance on antidepressants. These include updated reimbursement guidelines for doctors assisting patients in discontinuing medication, data-sharing on prescribing patterns, and expanded training programmes for healthcare providers.
US Health Secretary Robert F. Kennedy Jr. said psychiatric medications play a role in treatment but should not automatically be the default option. He also emphasised that patients currently using such medicines are not being advised to stop them abruptly.
Antidepressants are widely used in the United States, with estimates suggesting that a significant portion of adults are currently on such medications. SSRIs remain among the most commonly prescribed first-line treatments for depression and anxiety disorders, according to psychiatric associations.
Medical professionals, however, have warned against restricting access to these drugs, arguing that they are essential for treating mental health conditions and should be prescribed based on clinical need.
Experts in psychiatry note that SSRIs are generally considered safer than older antidepressants, though they can still produce side effects such as sleep disturbances, weight changes, sexual dysfunction and gastrointestinal issues. Regulators have also previously issued warnings about potential risks in younger patients.
Critics of potential restrictions argue that limiting access could negatively impact patients who depend on these medications, particularly if policies are introduced without strong scientific justification.
Regulatory experts also point out that any major change in access or availability would require substantial evidence of harm outweighing benefits, and in many cases would involve lengthy review processes.
Health authorities maintain that antidepressants remain an important part of modern psychiatric treatment, while ongoing discussions reflect broader debates around prescribing practices, mental health care and medication use in the United States.